Is IRA becoming America’s HTA – ISPOR 2025
with Priti Jhingran, PhD and Tijana Ignjatovic, MA, PhD of Genesis Research Group
IRA Medicare drug price negotiation program introduces a negotiation mechanism for US drug pricing with HTA-like features. This raises the question of whether IRA is a de-facto HTA body – requiring clinical, economic, and RWE in a manner reminiscent of established HTA systems, and potentially shortening the profitable lifecycle for branded products.
